ClinicalTrials.gg
CompletedNCT02331680Updated Oct 22, 2019Results posted

A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

A Phase 2 interventional study of OPC-41061 and OPC-41061 in Chronic Renal Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 4 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-22.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Kidney Failure, Chronic with a site in Japan — 1 open to participants now, 3 under way, 2 of them phase 3. Kidney Failure, Chronic · Japan.

Enrollment
13th of 24
124 · median 127
Started
2014
with 2 others
Phase 2
7 of 30
none open now
Registered
25th of 30
by date
Lead sponsor
3 of 30
Otsuka Pharmaceutical Co., Ltd.

Among the 30 studies in Kidney Failure, Chronic with a site in Japan, this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 25th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

1 of the 30 studies in Kidney Failure, Chronic with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Kidney Failure, Chronic with a site in Japan, or all of them as a file.
02

Study summary

This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration and who have daily urine volume of at least 500 mL/day.

03

Conditions studied

  • Chronic Renal Failure

Keywords

  • Undergoing Hemodialysis
  • Undergoing Hemodiafiltration
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic renal failure requiring hemodialysis or hemodiafiltration 3 times a week
  • Daily urine volume of ≥ 500 mL/day
  • Male or female patients age 20 to 80 years, inclusive
  • Use of one of the specified methods until 4 weeks after final IMP administration
  • Capable of providing their own written prior to any trial-related procedures being performed

Exclusion criteria

Exclusion Criteria:

  • Patients with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
  • Patients with class IV heart failure
  • Patients with impaired hepatic function(chronic hepatitis, drug-induced liver injury)
  • Patients with serious ischemic heart disease who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
  • Patients with serious arrhythmia who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
  • Patients with serious secondary hyperparathyroidism(intact parathyroid hormone > 500 pg/mL)
  • Patients who are concomitantly undergoing peritoneal dialysis
  • Patients with a history of cerebrovascular disease or coronary artery disease within 4 weeks prior to , a history of to any ingredient of tolvaptan or benzazepine derivatives such as mozavaptan hydrochloride or a history of impaired hepatic function(chronic hepatitis, drug-induced liver injury)
  • Patients with any of the following abnormal laboratory values: \< 8.0 g/dL, total > 3.0 mg/dL, (GPT) or AST (GOT) > 2 times the upper limit of the reference range, serum sodium > upper limit of the reference range, serum sodium \< 125 mEq/L, or serum potassium > 6.0 mEq/L
  • Patients who are unable to sense thirst or who have difficulty with fluid intake
  • Patients who have received OPC-41061 in history.
  • Participation in any other clinical trial or post-marketing clinical study within 4 weeks prior to informed consent for the present trial
  • Female patients who are pregnant, possibly pregnant, or nursing
  • Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    OPC-41061 15mg/day

    Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.

    Drug: OPC-41061

  • Experimental
    OPC-41061 30mg/day

    Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks

    Drug: OPC-41061

  • Placebo comparator
    Placebo

    Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.

    Drug: Placebo

Interventions

  • Also known as: Tolvaptan

  • Also known as: Tolvaptan

  • DrugPlacebo

    Also known as: Blank Tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daily Urine Volume

    Change in daily urine volume from baseline to the end of the treatment was calculated using descriptive statistics.

    Time frame: Baseline,End of the treatment

Secondary outcomes

  1. Change in Total Volume of Fluid Removed by Dialysis Per Week

    Change in total volume of fluid removed by dialysis per week from baseline to the end of the treatment was calculated using descriptive statistics.

    Time frame: Baseline,End of the treatment

07

Results

Posted Oct 22, 2019

Participant flow

Participant flow — Overall Study
MilestoneOPC-41061 15mg/DayOPC-41061 30mg/DayPlacebo
Started404044
Completed343629
Not completed6415
Withdrew: Adverse event302
Withdrew: Physician decision112
Withdrew: Withdrawal by subject012
Withdrew: Met withdrawal criteria225
Withdrew: Non-compliance with study drug001
Withdrew: Protocol violation003

Outcome measures

PrimaryChange From Baseline in Daily Urine Volume

Change in daily urine volume from baseline to the end of the treatment was calculated using descriptive statistics.

Time frame:
Baseline,End of the treatment
Reported as:
Mean · mL
Change From Baseline in Daily Urine Volume
mLOPC-41061 15mg/DayOPC-41061 30mg/DayPlacebo
Change From Baseline in Daily Urine Volume169.2 ± 422.2111.8 ± 557.7-259.9 ± 463.8
SecondaryChange in Total Volume of Fluid Removed by Dialysis Per Week

Change in total volume of fluid removed by dialysis per week from baseline to the end of the treatment was calculated using descriptive statistics.

Time frame:
Baseline,End of the treatment
Reported as:
Mean · mL
Change in Total Volume of Fluid Removed by Dialysis Per Week
mLOPC-41061 15mg/DayOPC-41061 30mg/DayPlacebo
Change in Total Volume of Fluid Removed by Dialysis Per Week485.9 ± 1979.3375.4 ± 1721.81099.5 ± 2160.5

Adverse events

Collected over Treatment period. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-41061 15mg/Day0/39 (0%)6/39 (15.4%)34/39 (87.2%)
OPC-41061 30mg/Day0/39 (0%)7/39 (17.9%)38/39 (97.4%)
Placebo0/44 (0%)10/44 (22.7%)34/44 (77.3%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventOPC-41061 15mg/DayOPC-41061 30mg/DayPlacebo
Shunt stenosisInjury, poisoning and procedural complications0/391/392/44
Acute myocardial infarctionCardiac disorders1/390/390/44
Angina pectorisCardiac disorders1/390/390/44
Cardiac failureCardiac disorders1/390/390/44
Cardiac failure congestiveCardiac disorders0/391/390/44
Shunt occlusionInjury, poisoning and procedural complications0/391/390/44
ContusionInjury, poisoning and procedural complications0/391/390/44
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/391/390/44
Macular holeEye disorders0/391/390/44
Decreased activityGeneral disorders1/390/390/44
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOPC-41061 15mg/DayOPC-41061 30mg/DayPlacebo
NasopharyngitisInfections and infestations9/3914/3910/44
ContusionInjury, poisoning and procedural complications1/397/393/44
DiarrhoeaGastrointestinal disorders1/395/394/44
VomitingGastrointestinal disorders2/394/391/44
ThirstGeneral disorders4/393/391/44
Shunt stenosisInjury, poisoning and procedural complications0/392/394/44
Blood potassium increasedInvestigations2/390/394/44
Blood pressure decreasedInvestigations3/391/392/44
Musculoskeletal painMusculoskeletal and connective tissue disorders3/390/391/44
WoundInjury, poisoning and procedural complications2/390/393/44

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OPC-41061 15mg/DayOPC-41061 30mg/DayPlaceboTotal
<=18 years0000
Between 18 and 65 years17262265
>=65 years23142259
Age, Continuous
Age, Continuous(years)OPC-41061 15mg/DayOPC-41061 30mg/DayPlaceboTotal
Mean64.2 ± 11.060.5 ± 12.664.4 ± 8.763.0 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061 15mg/DayOPC-41061 30mg/DayPlaceboTotal
Female5114056
Male3529468
Region of Enrollment
Region of Enrollment(participants)OPC-41061 15mg/DayOPC-41061 30mg/DayPlaceboTotal
Japan404044122
08

Study locations

4 sites
  • Kanto, Region, Japan
  • Kinki, Region, Japan
  • Kyushu, Region, Japan
  • Tohoku, Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2014
First posted
Jan 6, 2015
Start
Dec 2014
Primary completionActual
May 2016
CompletionActual
May 2016
Results first posted
Oct 22, 2019
Last update
Oct 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02331680
Responsible party
Sponsor
First posted
Jan 6, 2015
Start date
Dec 2014
Primary completion
May 2016
Completion
May 2016
Results posted
Oct 22, 2019
Last update
Oct 22, 2019

Study contacts

Hiroaki Ono, Mr.
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion